BioCentury | Oct 3, 2020
Product Development

Oral drugs and treatments for life-threatening diseases stand out among new product launches

...and prioritized virtual channels to engage with patients, physicians and pharmacies. Another oral CGRP inhibitor, Ubrelvy ubrogepant...
...siponimod (BAF312) Evenity, romosozumab (AMG 785, CDP7851, anti-sclerostin antibody) Reblozyl, luspatercept-aamt (ACE-536) Nurtec ODT, rimegepant (BHV-3000, bms-927711) Ubrelvy, ubrogepant (MK-1602) Tepezza...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...of two CNS drugs approved at the tail end of 2019. The other was Ubrelvy ubrogepant...
BioCentury | Dec 30, 2019
Clinical News

Migraine readout completes December hat trick for surging Axsome

...of pain. This month, FDA approved the first oral small molecule CGRP receptor antagonist, Ubrelvy ubrogepant...
BioCentury | Dec 24, 2019
Company News

Regulatory roundup: BioMarin poised to have first U.S., EU hemophilia gene therapy; plus Allergan, Eisai, FibroGen, ViiV and Vero

...FDA Also on Monday, FDA approved the first oral small molecule CGRP receptor antagonist, Ubrelvy ubrogepant...
...Orexin 1 receptor; OX2R (HCRTR2) - Orexin 2 receptor Sandi Wong, Staff Writer valoctocogene roxaparvovec (bmn 270) ubrogepant (MK-1602) lemborexant...
BioCentury | Jun 7, 2019
Company News

June 7 Company Quick Takes: Expanded label for PTC’s DMD drug; plus Achaogen, ICER on migraine and Nucala

...migraine treatments: CGRP receptor antagonists Zydis rimegepant from Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) and ubrogepant...
...Brand), SB-240563 (Compound #), Bosatria (Former), mepolizumab (Generic), Nucala (Other) oral lasmiditan (LY573144, Oral COL-144, IY573144) ubrogepant (MK-1602) Zemdri...
BioCentury | Feb 5, 2019
Company News

FDA psychiatry product division director joins Allergan

...Phase III data in 2019. Allergan and Merck & Co. Inc. (NYSE:MRK) are partnered on ubrogepant...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...breast cancer Phase III data 1Q19 Merck & Co. Inc. (NYSE:MRK) / Allergan plc (NYSE:AGN) Ubrogepant...
BioCentury | Oct 19, 2018
Company News

Express Scripts adds Aimovig, Emgality to new value-based migraine program; excludes Ajovy

...NYSE:AGN) announced plans to submit an NDA by 1Q19 seeking approval of its CGRP-targeting ubrogepant (MK-1602...
...small molecule was well tolerated in the Phase III UBR-MD-04 and Phase I 3110-105-002 trials. Ubrogepant...
...Petach Tikva, Israel Business: Neurology Jennie Walters Aimovig, erenumab (AMG 334) Ajovy, fremanezumab (TEV-48125, lbr-101, rn-307) Emgality, galcanezumab (LY2951742) ubrogepant (MK-1602) Allergan...
BioCentury | Oct 17, 2018
Company News

Express Scripts adds Aimovig, Emgality to new value-based migraine program; excludes Ajovy

...NYSE:AGN) announced plans to submit an NDA by 1Q19 seeking approval of its CGRP-targeting ubrogepant (MK-1602...
...small molecule was well tolerated in the Phase III UBR-MD-04 and Phase I 3110-105-002 trials. Ubrogepant...
BioCentury | Sep 8, 2018
Product Development

Data distribution

...liver enzymes across the blinded treatment and placebo groups in two Phase III studies of ubrogepant...
Items per page:
1 - 10 of 22